Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Human Genome Epidemiology Literature Finder|Home|PHGKB

Human Genome Epidemiology Literature Finder


Last data update: Jan 25, 2025. (Total: 235671Documents)
   dataset        GWAS Only
Filtered By:

Previous    

Records 1 - 13 (of 13 Records)

Query Trace: Myocardial Infarction and CYP3A4[original query]
Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
DNA and cell biology 2010 Oct 29 (10): 629-37.
Poduri Aruna, Khullar Madhu, Bahl Ajay, Sehrawat B S, Sharma Yashpaul, Talwar Kewal
Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention.
Heart (British Cardiac Society) 2012 Sep 98 (18): 1366-72.
Park Kyung Woo, Kang Jeehoon, Park Jin Joo, Yang Han-Mo, Lee Hae-Young, Kang Hyun-Jae, Koo Bon-Kwon, Oh Byung-Hee, Park Young-Bae, Kim Hyo-S
The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 2013 Jul 9 (3): 316-27.
Liang Zhen-Yang, Han Ya-Ling, Zhang Xiao-Lin, Li Yi, Yan Cheng-Hui, Kang Ji
Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
JACC. Cardiovascular interventions 2013 Nov 6 (11): 11.
Viviani Anselmi C, Briguori C, Roncarati R, Papa L, Visconti G, Focaccio A, De Micco F, Latronico MV, Pagnotta P, Condorelli G
No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarction.
Pharmacogenomics 2014 Aug 15 (11): 1471-7.
Leusink Maarten, de Keyser Catherine E, Onland-Moret N Charlotte, Hofman Albert, Visser Loes E, Stricker Bruno H, de Bakker Paul I W, de Boer Anthonius, van Schaik Ron H N, Maitland-van der Zee Anke Hil
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. GWAS Catalog
European heart journal 2015 Aug 36 (29): 1901-12.
Varenhorst Christoph, Eriksson Niclas, Johansson Åsa, Barratt Bryan J, Hagström Emil, Åkerblom Axel, Syvänen Ann-Christine, Becker Richard C, James Stefan K, Katus Hugo A, Husted Steen, Steg Ph Gabriel, Siegbahn Agneta, Voora Deepak, Teng Renli, Storey Robert F, Wallentin Lars,
Concomitant Use of Proton-Pump Inhibitors and Clopidogrel Increases the Risk of Adverse Outcomes in Patients With Ischemic Stroke Carrying Reduced-Function CYP2C19*2.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2016 Sep .
Yi Xingyang, Han Zhao, Zhou Qiang, Cheng Wen, Lin Jing, Wang Ch
Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population.
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2016 Aug .
Yi Xingyang, Zhou Qiang, Wang Chun, Lin Jing, Cheng Wen, Chi Lif
Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study.
Medicine 2016 Jan 95 (2): e2487.
Wang Yi-Chun, Hsieh Tsung-Cheng, Chou Chu-Lin, Wu Jung-Lun, Fang Te-Ch
Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect.
Frontiers in pharmacology 2017 1 7 494.
Ing Lorenzini Kuntheavy, Daali Youssef, Fontana Pierre, Desmeules Jules, Samer Caroli
Efficacy of P2Y12 Receptor Blockers After Myocardial Infarction and Genetic Variability of their Metabolic Pathways.
Current vascular pharmacology 2018 2 17 (1): 35-40.
Máchal Jan, Hlinomaz O
CYP2C19 and CYP3A4 activity and ADP-induced platelet reactivity in prasugrel- or ticagrelor-treated STEMI patients: monocentric study in PRAGUE-18 trial participants.
Xenobiotica; the fate of foreign compounds in biological systems 2020 Feb 1-22.
Máchal J, Hlinomaz O, Kostolanská K, Peš O, Máchalová A, Šplíchal Z, Mot'ovská Z, Ju?ica
Effects of CYP3A4*22 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-study.
Frontiers in pharmacology 2022 12 13 1032995.
Azzahhafi Jaouad, Bergmeijer Thomas O, van den Broek Wout W A, Chan Pin Yin Dean R P P, Rayhi Senna, Peper Joyce, Bor Willem L, Claassens Daniel M F, van Schaik Ron H N, Ten Berg Jurriën
TOP